Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent Glioblastoma Multiforme: Interim results No significant financial relationships to disclose. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results